Physician profile
Jonathon J Rynning
NPI 1992845127
$10,885.16
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $1,149 · 2021: $1,920 · 2022: $2,423 · 2023: $2,966 · 2024: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,794.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,204.08 | 2021-2024 | Vraylar |
| Lundbeck LLC | $1,059.78 | 2019-2024 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $808.85 | 2019-2023 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $799.36 | 2019-2024 | Austedo Xr, Austedo |
| Allergan, INC. | $764.45 | 2019-2020 | |
| Alkermes, INC. | $741.17 | 2021-2023 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $603.39 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $550.72 | 2019-2024 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $426.87 | 2020-2024 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $418.55 | 2019-2022 | |
| Tris Pharma INC | $395.08 | 2022-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $367.86 | 2021-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $349.26 | 2019-2024 | Ingrezza |
| Almatica Pharma LLC | $347.63 | 2021-2024 | Loreev Xr, Sertraline Hcl |
| Jazz Pharmaceuticals INC. | $223.25 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $216.77 | 2023-2024 | Xelstrym, Secuado |
| Corium, LLC | $205.53 | 2022-2024 | Azstarys |
| Indivior INC. | $202.05 | 2021-2024 | Perseris |
| Vanda Pharmaceuticals INC. | $144.40 | 2019-2022 | |
| Bausch Health US, LLC | $142.38 | 2019-2023 | Wellbutrin, Aplenzin |
| Avanir Pharmaceuticals, INC. | $142.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $139.91 | 2020-2023 | Belsomra |
| Axsome Therapeutics, INC. | $137.89 | 2022-2024 | Auvelity |
| Shire North American Group INC | $110.28 | 2019 | |
| Idorsia Pharmaceuticals US INC | $97.77 | 2023 | Quviviq |
| Eisai INC. | $80.69 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $72.29 | 2019-2023 | Jornay Pm |
| Acadia Pharmaceuticals INC | $40.48 | 2021 | |
| Brainsway USA INC | $34.33 | 2023-2024 | Brainsway Deep Tms System |
| Neos Therapeutics, LP | $22.82 | 2023 | Adzenys Xr-Odt |
| Adlon Therapeutics L.P. | $21.65 | 2019 | |
| Alfasigma USA, INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathon Rynning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.